Internal Medicine, Endocrinology, Diabetes, & Metabolism · Vero Beach, FL
NPI
1881777332
Since 2006
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
1
Medicare group memberships
Hospitals
3
Hospital affiliations
2835 20th Street, Building C
Vero Beach, FL, 32960
Phone (772) 299-3003
Groups this clinician bills Medicare through
Medicare paid, 2024
$991K
54,997 services
Medicare patients, 2024
1,885
Average age 76
Drug cost, 2024
$2.6M
7,754 prescriptions
Company payments, 2025
$725
From 10 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Paul A Graham was code 99214 (office e&m - established), 3,389 times for 1,543 patients. In total Paul A Graham billed 54,997 services in 66 codes, and Medicare paid $991K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2007-07-08.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 3,389 | 1,543 | $93.02 | $315K |
| 36415 Venipuncture Blood Collection | Office | 3,247 | 1,433 | $8.65 | $28K |
| 84443 Clinical Chemistry | Office | 3,120 | 1,427 | $16.45 | $51K |
| 84439 Clinical Chemistry | Office | 3,119 | 1,425 | $8.84 | $28K |
| 84481 Clinical Chemistry | Office | 3,094 | 1,405 | $16.58 | $51K |
| 80053 Clinical Chemistry | Office | 2,855 | 1,253 | $10.34 | $30K |
| 80061 Clinical Chemistry | Office | 2,692 | 1,202 | $13.10 | $35K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 2,661 | 1,380 | $12.81 | $34K |
| 82550 Clinical Chemistry | Office | 2,623 | 1,143 | $6.37 | $17K |
| 85025 Blood Count | Office | 2,592 | 1,217 | $7.61 | $20K |
| 83036 Blood Count | Office | 2,582 | 1,132 | $9.51 | $25K |
| 82607 Clinical Chemistry | Office | 2,445 | 1,156 | $14.76 | $36K |
| 83540 Clinical Chemistry | Office | 2,442 | 1,148 | $6.33 | $15K |
| 83550 Clinical Chemistry | Office | 2,439 | 1,148 | $8.56 | $21K |
| 82746 Clinical Chemistry | Office | 2,438 | 1,151 | $14.39 | $35K |
By year: 2022 $354K for 18,068 services; 2023 $728K for 37,678 services; 2024 $991K for 54,997 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 3,247 | 1,433 | $8.65 | $28K |
| 84443 Clinical Chemistry | 3,120 | 1,427 | $16.45 | $51K |
| 84439 Clinical Chemistry | 3,119 | 1,425 | $8.84 | $28K |
| 84481 Clinical Chemistry | 3,094 | 1,405 | $16.58 | $51K |
| 80053 Clinical Chemistry | 2,855 | 1,253 | $10.34 | $30K |
| 80061 Clinical Chemistry | 2,692 | 1,202 | $13.10 | $35K |
| 82550 Clinical Chemistry | 2,623 | 1,143 | $6.37 | $17K |
| 85025 Blood Count | 2,592 | 1,217 | $7.61 | $20K |
| 83036 Blood Count | 2,582 | 1,132 | $9.51 | $25K |
| 82607 Clinical Chemistry | 2,445 | 1,156 | $14.76 | $36K |
Medicare prescription drug claims, 2024
In 2024, the drug Paul A Graham prescribed most often to Medicare patients was Levothyroxine Sodium, with 1,020 prescriptions and refills. In total Paul A Graham wrote 7,754 Medicare prescriptions that cost $2.6M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Levothyroxine Sodium Generic | 1,020 | 2,786 | 292 | $12K |
| Metformin Hcl Generic | 546 | 1,569 | 172 | $4,355 |
| Metformin Hcl Er Metformin Hcl | 449 | 1,199 | 144 | $5,427 |
| Synthroid Levothyroxine Sodium | 431 | 1,037 | 112 | $40K |
| Mounjaro Tirzepatide | 392 | 431 | 59 | $435K |
| Ozempic Semaglutide | 351 | 510 | 75 | $456K |
| Jardiance Empagliflozin | 248 | 416 | 55 | $229K |
| Trulicity Dulaglutide | 216 | 324 | 45 | $309K |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 169 | 472 | 68 | $20K |
| Farxiga Dapagliflozin Propanediol | 162 | 312 | 39 | $168K |
| Rosuvastatin Calcium Generic | 161 | 469 | 58 | $2,857 |
| Lisinopril Generic | 155 | 389 | 43 | $966 |
| Glipizide Generic | 138 | 395 | 47 | $1,846 |
| Glimepiride Generic | 131 | 383 | 41 | $1,628 |
| Nateglinide Generic | 127 | 334 | 38 | $11K |
Brand drugs: 3,734 claims; generic drugs: 3,651 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Paul A Graham $725 ($725 in general payments such as food, travel and fees) from 10 companies. The largest payer was Novo Nordisk Inc with $224.
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc NVO | 10 | $224 |
| Lilly USA, LLC LLY | 6 | $198 |
| Corcept Therapeutics CORT | 4 | $97.46 |
| Abbott Laboratories ABT | 3 | $66.55 |
| Novartis Pharmaceuticals Corporation NVS | 1 | $28.53 |
| Medtronic, Inc. MDT | 1 | $25.04 |
| Mannkind Corporation MNKD | 1 | $24.82 |
| Neurocrine BioSciences, Inc. NBIX | 1 | $23.95 |
| Sanofi-Aventis U.S. LLC SNY | 1 | $19.59 |
| Dexcom, Inc. DXCM | 1 | $17.38 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.